Profile
| Metric | Value |
|---|---|
| Full Name | Mineralys Therapeutics, Inc. |
| Ticker | NASDAQ: MLYS |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | mineralystx.com |
| Employees | 51 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $35.35 | |
| Price, 1D Change | -1.01% | |
| Market Cap | $3B | |
| - | ||
| PE Ratio | - | |
| Beta | 0.33 | |
| Revenue | $0 | |
| Revenue, 1Y Change | 0.00% | |
| EPS | -$3.66 | |
| EPS, 1Y Change | -84.38% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$3.66 | |
| EPS Estimate | -$2.40 | |
| EPS Est. Change | +34.56% | |
| Revenue | $0.00 | |
| Revenue Estimate | - | |
| Revenue Est. Change | - | |
| Current Price | $35.35 | |
| Price Target | - | $53.00 |
| Price Tgt. Change | - | +49.93% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$2.28 | -$1.99 | +12.86% | |
| -$3.69 | -$3.66 | +0.59% | |
| -$2.40 | N/A | +34.56% | |
| -$2.31 | N/A | +37.03% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| - | $0.00 | - | |
| - | $0.00 | - | |
| - | N/A | - | |
| $3.30M | N/A | - |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +172.34% | |
| Price, 3Y | - | |
| Market Cap, 1Y | +332.60% | |
| Market Cap, 3Y | - | |
| Revenue, 1Y | 0.00% | |
| Revenue, 3Y | 0.00% | |
| EPS, 1Y | -84.38% | |
| EPS, 3Y | -915.86% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $35.35 | |
| SMA 200 | $25.43 | |
| SMA 200 vs Price | -28.06% | |
| SMA 50 | $39.40 | |
| SMA 50 vs Price | +11.45% | |
| Beta | 0.33 | |
| ATR | $1.86 | |
| 14-Day RSI | 36.90 | |
| 10-Day Volatility | 23.51% | |
| 1-Year Volatility | 116.68% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $0.00 | |
| EPS | -$3.66 | |
| Gross Profit | -$43.00K | |
| - | ||
| Operating Profit | -$192.40M | |
| - | ||
| Net Income | -$177.81M | |
| - | ||
| EBITDA | -$192.36M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.00 | |
| Current Ratio | 14.02 | |
| Quick Ratio | 14.02 | |
| - | ||
| - | ||
| Altman Z-Score | 110.58 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | - | |
| PB Ratio | 4.85 | |
| EV/EBITDA | -11.98 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $191.26M | |
| Cash & Equivalents | $114.09M | |
| Total Assets | $205.90M | |
| Current Assets | $205.35M | |
| Total Liabilities | $14.65M | |
| Current Liabilities | $14.65M | |
| Total Debt | $0.00 | |
| Short Term Debt | $0.00 | |
| Accounts Payable | $479.00K |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $192.40M | |
| Operating Expenses | $192.40M | |
| Cost Of Goods Sold | $43.00K | |
| SG&A | $23.82M | |
| D&A | $43.00K | |
| Interest Expense | $0.00 | |
| Income Tax | $0.00 |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$166.31M | |
| CFI | $114.96M | |
| CFF | $116.14M | |
| Capex | $96.00K | |
| Free Cash Flow | -$166.41M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Stifel | → | |
| HC Wainwright & Co. | → | |
| Wells Fargo | → | |
| HC Wainwright & Co. | → | |
| Wells Fargo | → | |
| Goldman Sachs | → | |
| HC Wainwright & Co. | → | |
| Jefferies | → | |
| B of A Securities | → | |
| HC Wainwright & Co. | → |
Analyst sentiment
Institutional ownership
Screeners with MLYS
Data Sources & References
- MLYS Official Website mineralystx.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1933414/000193341425000142/0001933414-25-000142-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1933414/000193341425000009/0001933414-25-000009-index.htm
- MLYS Profile on Yahoo Finance finance.yahoo.com/quote/MLYS
- MLYS Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/mlys
FAQ
What is the ticker symbol for Mineralys Therapeutics, Inc.?
The ticker symbol for Mineralys Therapeutics, Inc. is NASDAQ:MLYS
Does Mineralys Therapeutics, Inc. pay dividends?
No, Mineralys Therapeutics, Inc. does not pay dividends
What sector is Mineralys Therapeutics, Inc. in?
Mineralys Therapeutics, Inc. is in the Healthcare sector
What industry is Mineralys Therapeutics, Inc. in?
Mineralys Therapeutics, Inc. is in the Biotechnology industry
What country is Mineralys Therapeutics, Inc. based in?
Mineralys Therapeutics, Inc. is headquartered in United States
When did Mineralys Therapeutics, Inc. go public?
Mineralys Therapeutics, Inc. initial public offering (IPO) was on February 10, 2023
Is Mineralys Therapeutics, Inc. in the S&P 500?
No, Mineralys Therapeutics, Inc. is not included in the S&P 500 index
Is Mineralys Therapeutics, Inc. in the NASDAQ 100?
No, Mineralys Therapeutics, Inc. is not included in the NASDAQ 100 index
Is Mineralys Therapeutics, Inc. in the Dow Jones?
No, Mineralys Therapeutics, Inc. is not included in the Dow Jones index
When was Mineralys Therapeutics, Inc. last earnings report?
Mineralys Therapeutics, Inc.'s most recent earnings report was on November 10, 2025
When does Mineralys Therapeutics, Inc. report earnings?
The next expected earnings date for Mineralys Therapeutics, Inc. is February 12, 2026